The USJBC stands by the concerns expressed in its recent letter to the Japanese Ministry of Health, Labor and Welfare (MHLW), which Minister Fukuoka was questioned on by the press. Japan’s approach to drug pricing should be fair, transparent, and provide meaningful opportunity for stakeholder inputs. https://lnkd.in/ganxP4pT
